Farazmandfar Touraj, Haghshenas Mohammad Reza, Shahbazi Majid
1 Department of Molecular Medicine, Faculty of Advanced Medical Technologies, Golestan University of Medical Sciences, Gorgan, Iran.
2 Molecular and Cell Biology Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
Hum Gene Ther. 2015 Oct;26(10):680-7. doi: 10.1089/hum.2015.031. Epub 2015 Aug 6.
Today, lentiviral vectors are favorable vectors for RNA interference delivery in anti-HIV therapeutic approaches. Nevertheless, problems such as the specific recognition of target cells and uncontrolled expression of the transgene can restrict their use in vivo. Herein we present a new HIV-inducible promoter to express anti-HIV short hairpin RNA (shRNA) by RNA Pol II in mammalian cells. We likewise showed a novel third-generation lentiviral vector system with more safety and a specific tropism to the target cells. The new promoter, CkRhsp, was constructed from the chicken β-actin core promoter with the R region of HIV-1 long terminal repeat fused upstream of minimal hsp70 promoter. This system was induced by HIV-1 Tat, and activates transcription of two shRNAs against two conserved regions of HIV-1 transcripts produced in two steps of the virus life cycle. We also mimicked HIV-1 cell tropism by using the HIV-1 envelope in structure of third-generation lentiviral vector. The new fusion promoter efficiently expressed shRNA in a Tat-inducible manner. HIV-1 replication was inhibited in transient transfection and stable transduction assays. The new viral vector infected only CD4+cells. CkRhsp promoter may be safer than other inducible promoters for shRNA-mediated gene therapies against HIV. The use of the wild envelope in the vector packaging system may provide the specific targeting T lymphocytes and hematopoietic stem cells for anti-HIV-1 therapeutic approaches in vivo.
如今,慢病毒载体是抗HIV治疗方法中用于RNA干扰传递的理想载体。然而,诸如靶细胞的特异性识别和转基因的失控表达等问题可能会限制其在体内的应用。在此,我们提出一种新的HIV诱导型启动子,用于在哺乳动物细胞中通过RNA聚合酶II表达抗HIV短发夹RNA(shRNA)。我们同样展示了一种新型的第三代慢病毒载体系统,其具有更高的安全性和对靶细胞的特异性嗜性。新的启动子CkRhsp由鸡β-肌动蛋白核心启动子构建而成,HIV-1长末端重复序列的R区域融合在最小hsp70启动子的上游。该系统由HIV-1 Tat诱导,并激活针对在病毒生命周期两个步骤中产生的HIV-1转录本两个保守区域的两个shRNA的转录。我们还通过在第三代慢病毒载体结构中使用HIV-1包膜来模拟HIV-1细胞嗜性。新的融合启动子以Tat诱导的方式有效表达shRNA。在瞬时转染和稳定转导试验中,HIV-1复制受到抑制。新的病毒载体仅感染CD4+细胞。对于针对HIV的shRNA介导的基因治疗,CkRhsp启动子可能比其他诱导型启动子更安全。在载体包装系统中使用野生型包膜可为体内抗HIV-1治疗方法提供特异性靶向T淋巴细胞和造血干细胞。